TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04208945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 500000 units of inhaled colistin three times daily for 10 days
Study: NCT00915252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy.
Study: NCT01670760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-heat-flux thermometry
Description: The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
Study: NCT02450799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrylic IOL
Description: Acrylic IOL for long-term implantation in the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone IOL
Description: Silicone IOL for long-term implantation in the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA IOL
Description: Polymethylmethacrylate IOL for long-term implantation in the cataract patient
Study: NCT04612959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosexual care
Description: The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
Study: NCT01312012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiviral therapy
Description: 100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level \> 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
Study: NCT00601094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus CCL21 vaccine
Description: Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
Study: NCT02650882

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device POWERbreathe

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Device POWERbreathe
Study: NCT04773197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beating the Blues (BtB)
Description: Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
Study: NCT00915252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Description: Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5
Study: NCT01969136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02351817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Ostomy appliance
Study: NCT04773197

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entertain Me Well (EMW)
Description: Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
Study: NCT04782466

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Intervention
Description: The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist attention-control
Description: For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
Study: NCT03759951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-1
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-2
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed twice per week on non-consecutive days for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-3
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed thrice per week on non-consecutive days for 12 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: No training will be performed during a 1-year period. Participation only in measurements.
Study: NCT00972452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: short period of exercise training (5-10 days)
Study: NCT01748877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXN-462
Description: Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
Study: NCT01704768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPE/Healthy Lifestyles TEEN Program.
Description: The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Teens Attention Control Program
Description: The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
Study: NCT00836095

Intervention type: DEVICE
Group type: OTHER
Intervention: Supreme Laryngeal mask airway
Description: Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Proseal laryngeal mask airway
Description: Proseal is a multiple use, variant of the laryngeal mask airway
Study: NCT02947269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride 2mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Placebo capsule
Study: NCT01795482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Description: In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forced-air warming
Description: In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
Study: NCT02830971

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doing Different ICU techniques and skills
Study: NCT03794687

Intervention type: PROCEDURE
Intervention: Left heart catheterization
Description: Catheterization via the distal radial artery
Study: NCT03575988

Intervention type: OTHER
Intervention: Diabetes
Description: The patients have diabetes without diabetic retinopathy from the diabetic outpatient

Intervention type: OTHER
Intervention: Diabetes
Description: The patients have diabetes without diabetic retinopathy from the diabetic outpatient
Study: NCT03946579

Intervention type: OTHER
Group type: OTHER
Intervention: self questionnaires
Description: FSFI, QLQ-C30, BR23, ELD15, HADS, GDS 15, FACIT, BIS
Study: NCT02351817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Ostomy appliance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baseline
Description: Ostomy appliance
Study: NCT02488915

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmboTrap® Revascularization Device
Study: NCT03146923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Current Low Phosphorus Diet Prescription
Description: Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides \<15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition \& Dietetic Institute (INDI) in 2010 and includes following main components:~* Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)~* Restricting dairy intake (1-1.5 portions per day)~* Avoiding foods high in phosphate~* Avoiding foods with phosphate additives

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Low Phosphorus Diet Prescription
Description: Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management~* Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate~* Increased focus on avoiding additives~* Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .~* Avoiding over-prescription of protein which carries an obligatory phosphorus load.~* Focus on high protein foods with a low phosphorus to protein ratio
Study: NCT04054986

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: F-Var3 PET/CT
Description: Participants will undergo up to 5 serial F-Var3 PET/CT scans within 25 minutes of the injection of 18F-Var3, 30, 60, 120 and 240 minutes after injection of the 18FVar3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Collection of blood for research tests before the injection, 30, 60, 120 and 240 min after the injection.
Study: NCT03823521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cardioplegia Solution
Description: Cardioplexol™ will be adminstered in cardiac surgery as cardioplegic solution
Study: NCT03820843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy and standard orthophonic rehabilitation
Description: In addition to standard orthophonic rehabilitation, the patient will receive 12 sessions of art therapy
Study: NCT01614886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: 1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ENA713
Description: -3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
Study: NCT01980017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ottawa Model for Smoking Cessation
Study: NCT00190749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 5-20 mg, oral, capsules, daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: 2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
Study: NCT00518492

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Blood draws at 6 and 12 months following end of 6108A1-500 trial.
Study: NCT04235179

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR to a dose of 30Gy/5 to the pelvis (vaginal and paravaginal tissues as well as regional lymph nodes)
Study: NCT01845909

Intervention type: OTHER
Intervention: ECG and survey screening
Study: NCT01025401

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: 3-D accelerometric and magnetic sensors
Description: sensors are positioned on the right wrist, the left wrist and on the head.
Study: NCT03592550

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Abdominal ultrasound imaging of the liver

Intervention type: DEVICE
Intervention: Ultrasound imaging
Description: Abdominal ultrasound imaging of the liver
Study: NCT04032054

Intervention type: DEVICE
Intervention: mono-axial and poly-axial screws
Description: types of pedicular screws for thoracolumbar fractures fixation

Intervention type: DEVICE
Intervention: mono-axial and poly-axial screws
Description: types of pedicular screws for thoracolumbar fractures fixation
Study: NCT04495101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prolastin
Description: Intravenous infusion 120 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard medical treatment per local policies or guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard medical treatment per local policies or guidelines
Study: NCT01607632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: loving-kindness meditation
Description: A 12-week duration, 90 minute per session loving-kindness meditation course
Study: NCT02073747

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: One hour inhaled normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: One hour inhaled ten milligrams of albuterol
Study: NCT03664089

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ankle weights (2.5 pounds [1.1 kg]/ankle)
Description: Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week, ankle weights (2.5 pounds \[1.1 kg\]/ankle), documentation for ankle weight usage, an accelerometer, and instructions for accelerometer usage.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Women will receive the standard recommendation for engaging in 150 minutes of physical activity per week.
Study: NCT02270515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home for Kidney Disease (PCMH-KD)
Description: A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
Study: NCT04328883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral and inhaled ASA formulations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Oral and inhaled ASA formulations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Oral and inhaled ASA formulations
Study: NCT00398554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: 25mg/m²/day, 2 hours i.v.infusion on day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: 150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine sulfate
Description: 6 mg/m² i.v. bolus on day 1 and day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
Study: NCT03733015

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial Magnetic Stimulation (rTMS) can be used to temporary modify the brain activity.
Study: NCT03216512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Noise Cancelling Headphones
Description: During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of Noise Cancelling Headphones
Description: During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
Study: NCT01748292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg ranibizumab
Description: Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Description: Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.